Inamed Obesity, Breast Implant, Facial Aesthetics Sales Spur Strong Q3
This article was originally published in The Gray Sheet
Executive Summary
Data on Inamed's next-generation silicone breast implant could allay concerns voiced by FDA's General & Plastic Surgery Devices Panel about the controversial device category, the firm maintains
You may also be interested in...
Inamed Stresses Hylaform Non-Inferiority; EU Clears Silicone Implant Safety
FDA's regulation of Genzyme's hyaluronic acid-based Synvisc osteoarthritic knee pain treatment could offer a precedent for labeling of the firm's Hylaform HA dermal filler
Inamed Stresses Hylaform Non-Inferiority; EU Clears Silicone Implant Safety
FDA's regulation of Genzyme's hyaluronic acid-based Synvisc osteoarthritic knee pain treatment could offer a precedent for labeling of the firm's Hylaform HA dermal filler
Gastric Bypass Surgery Alternative Weighed By Inamed For Teen Population
Inamed is considering an adolescent-use indication for its BioEnterics Lap-Band gastric intervention system, spurred by U.S. surgeon demand for a less invasive obesity treatment for patients under age 18